But lets do some fact checking.
FDA has provented any trial from been started from about 2020. Yet we still treated 71 adults with a probable survival at best 30% @ 100 days, yet our treatment got 63%. Not bad.
Is it not time for MSB to move its pathway to other global markets?
Take Japan. We need to be way more active , we are getting around 27% royalties from JCR. Temcell is a old product , must be time for that to be updated with our new product.
Trials, well US has stalled . What would the market be for IBD in Japan ? Yes JCR would do very well , we would too.
And this adult trial? Should we wait for the FDA to give the go or just start in the EU and see how long it takes for the US to say yes?
Ann: Mesoblast Corporate Presentation, page-25
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.40 |
Change
0.025(1.82%) |
Mkt cap ! $1.569B | |||
| Open | High | Low | Value | Volume |
| $1.40 | $1.41 | $1.38 | $959.8K | 687.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 7717 | $1.40 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.40 | 7344 | 2 |
View Market Depth
| Last trade - 10.36am 17/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |